• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急性心肌梗死后低密度脂蛋白胆固醇目标的达成:来自库里蒂巴市公共卫生系统的真实世界数据。

Achievement of LDL-Cholesterol Goals after Acute Myocardial Infarction: Real-World Data from the City of Curitiba Public Health System.

作者信息

Bernardi André, Olandoski Marcia, Erbano Lucas Olandoski, Guarita-Souza Luiz Cesar, Baena Cristina Pellegrino, Faria-Neto José Rocha

机构信息

Faculdade de Medicina, Pontifícia Universidade Católica do Paraná, Curitiba, PR - Brasil.

Hospital Universitário Evangélico Mackenzie, Curitiba, PR - Brasil.

出版信息

Arq Bras Cardiol. 2022 May 9;118(6):1018-25. doi: 10.36660/abc.20210328.

DOI:10.36660/abc.20210328
PMID:35544850
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9345156/
Abstract

BACKGROUND

Reduction of LDL-cholesterol (LDL-c) levels is the cornerstone in risk reduction, but many high-risk patients are not achieving the recommended lipid goals, even in high-income countries.

OBJECTIVE

To evaluate whether patients seen in the city of Curitiba public health system are reaching LDL-c goals after an acute myocardial infarction (AMI).

METHODS

This retrospective cohort explored the data of patients admitted with AMI between 2008 and 2015 in public hospitals from the city of Curitiba. In order to evaluate the attainment of the LDL-c target, we have used the last value registered in the database for each patient up to 2016. For those who had at least one LDL-c registered in the year before AMI, percentage of reduction was calculated. The level of significance adopted for statistical analysis was p<0.05.

RESULTS

Of 7,066 patients admitted for AMI, 1,451 were followed up in an out-patient setting and had at least one evaluation of LDL-c. Mean age was 60.8±11.4 years and 35.8%, 35.2%, 21.5%, and 7.4% of patients had LDL-c levels ≥100, 70-99, 50-69 and <50 mg/dL, respectively. Of these, 377 patients also had at least one LDL-c evaluation before the AMI. Mean LDL-c concentrations were 128.0 and 92.2 mg/dL before and after AMI, with a mean reduction of 24.3% (35.7 mg/dL). LDL-c levels were reduced by more than 50% in only 18.3% of the cases.

CONCLUSION

In the city of Curitiba public health system patients, after myocardial infarction, are not achieving adequate LDL-c levels after AMI.

摘要

背景

降低低密度脂蛋白胆固醇(LDL-c)水平是降低风险的基石,但即使在高收入国家,许多高危患者仍未达到推荐的血脂目标。

目的

评估库里蒂巴市公共卫生系统中的患者在急性心肌梗死(AMI)后是否达到LDL-c目标。

方法

这项回顾性队列研究探讨了2008年至2015年在库里蒂巴市公立医院因AMI入院的患者数据。为了评估LDL-c目标的达成情况,我们使用了数据库中截至2016年每位患者的最后记录值。对于那些在AMI前一年至少有一次LDL-c记录的患者,计算降低百分比。统计分析采用的显著性水平为p<0.05。

结果

在7066例因AMI入院的患者中,1451例在门诊接受随访,且至少有一次LDL-c评估。平均年龄为60.8±11.4岁,LDL-c水平≥100、70-99、50-69和<50mg/dL的患者分别占35.8%、35.2%、21.5%和7.4%。其中,377例患者在AMI前也至少有一次LDL-c评估。AMI前后LDL-c平均浓度分别为128.0和92.2mg/dL,平均降低24.3%(35.7mg/dL)。仅18.3%的病例LDL-c水平降低超过50%。

结论

在库里蒂巴市公共卫生系统的患者中,心肌梗死后未达到AMI后足够的LDL-c水平。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec89/9345156/b75f8caeecf5/0066-782X-abc-118-06-1018-gf04-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec89/9345156/2fe90a2e7964/0066-782X-abc-118-06-1018-gf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec89/9345156/d824d1a4f4b9/0066-782X-abc-118-06-1018-gf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec89/9345156/862392d8d978/0066-782X-abc-118-06-1018-gf03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec89/9345156/7fb1b8268f18/0066-782X-abc-118-06-1018-gf04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec89/9345156/b479005aa007/0066-782X-abc-118-06-1018-gf01-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec89/9345156/b3707a3e96a7/0066-782X-abc-118-06-1018-gf02-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec89/9345156/c473dcb623df/0066-782X-abc-118-06-1018-gf03-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec89/9345156/b75f8caeecf5/0066-782X-abc-118-06-1018-gf04-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec89/9345156/2fe90a2e7964/0066-782X-abc-118-06-1018-gf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec89/9345156/d824d1a4f4b9/0066-782X-abc-118-06-1018-gf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec89/9345156/862392d8d978/0066-782X-abc-118-06-1018-gf03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec89/9345156/7fb1b8268f18/0066-782X-abc-118-06-1018-gf04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec89/9345156/b479005aa007/0066-782X-abc-118-06-1018-gf01-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec89/9345156/b3707a3e96a7/0066-782X-abc-118-06-1018-gf02-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec89/9345156/c473dcb623df/0066-782X-abc-118-06-1018-gf03-en.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec89/9345156/b75f8caeecf5/0066-782X-abc-118-06-1018-gf04-en.jpg

相似文献

1
Achievement of LDL-Cholesterol Goals after Acute Myocardial Infarction: Real-World Data from the City of Curitiba Public Health System.急性心肌梗死后低密度脂蛋白胆固醇目标的达成:来自库里蒂巴市公共卫生系统的真实世界数据。
Arq Bras Cardiol. 2022 May 9;118(6):1018-25. doi: 10.36660/abc.20210328.
2
Dyslipidemia treatment and attainment of LDL-cholesterol treatment goals in patients participating in the Managed Care for Acute Myocardial Infarction Survivors program.在参加急性心肌梗死幸存者管理式医疗计划的患者中,血脂异常治疗和 LDL-胆固醇治疗目标的达成情况。
Kardiol Pol. 2023;81(4):359-365. doi: 10.33963/KP.a2023.0045. Epub 2023 Mar 5.
3
Comparison of the effects of two low-density lipoprotein cholesterol goals for secondary prevention after acute myocardial infarction in real-world practice: ≥ 50% reduction from baseline versus <70 mg/dL.急性心肌梗死后二级预防中两个低密度脂蛋白胆固醇目标在实际临床中的效果比较:较基线水平降低≥50%与<70 mg/dL。
Int J Cardiol. 2015;187:478-85. doi: 10.1016/j.ijcard.2015.03.386. Epub 2015 Mar 28.
4
Is non-HDL-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDL-cholesterol? : a retrospective study.与低密度脂蛋白胆固醇相比,非高密度脂蛋白胆固醇是否是急性心肌梗死后患者长期预后的更好预测指标?一项回顾性研究。
BMC Cardiovasc Disord. 2017 Jan 5;17(1):10. doi: 10.1186/s12872-016-0450-9.
5
Optimal low-density lipoprotein cholesterol target level in Korean acute myocardial infarction patients (<70 mg/dL vs. <55 mg/dL): Based on Korea acute myocardial infarction registry-National Institute of Health.韩国急性心肌梗死患者的最佳低密度脂蛋白胆固醇目标水平(<70mg/dL 与 <55mg/dL):基于韩国急性心肌梗死注册-国立卫生研究院。
Int J Cardiol. 2022 Mar 15;351:15-22. doi: 10.1016/j.ijcard.2021.12.020. Epub 2021 Dec 16.
6
Evaluation of Low-density Lipoprotein Cholesterol Target Attainment Rates According to the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society Dyslipidemia Guidelines for Secondary Prevention in Patients with Acute Myocardial Infarction.根据 2016 年和 2019 年欧洲心脏病学会/欧洲动脉粥样硬化学会急性心肌梗死二级预防血脂异常指南评估低密度脂蛋白胆固醇达标率。
Rev Invest Clin. 2021 Nov 5;73(3):371-378. doi: 10.24875/RIC.21000152.
7
Target-attainment rates of low-density lipoprotein cholesterol using lipid-lowering drugs one year after acute myocardial infarction in sweden.瑞典急性心肌梗死后一年内使用降脂药物的低密度脂蛋白胆固醇达标率。
Am J Cardiol. 2014 Jan 1;113(1):17-22. doi: 10.1016/j.amjcard.2013.09.007. Epub 2013 Oct 2.
8
Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i.急性心肌梗死患者低密度脂蛋白胆固醇(LDL-C)达标指南:一项显示前蛋白转化酶枯草溶菌素9抑制剂(PCSK9i)强化治疗影响的真实世界证据研究
Cardiol Ther. 2023 Jun;12(2):327-338. doi: 10.1007/s40119-022-00300-7. Epub 2023 Jan 19.
9
10
Achievement of LDL-cholesterol goal with statins after an st segment elevation myocardial infarction.ST段抬高型心肌梗死后使用他汀类药物实现低密度脂蛋白胆固醇目标。
J Med Assoc Thai. 2015 Feb;98(2):129-36.

引用本文的文献

1
Cardiovascular Statistics - Brazil 2023.心血管统计数据 - 巴西2023年
Arq Bras Cardiol. 2024 Feb;121(2):e20240079. doi: 10.36660/abc.20240079.
2
Assessing statins use in a real-world primary care digital strategy: a cross-sectional analysis of a population-wide digital health approach.评估他汀类药物在现实世界基层医疗数字策略中的使用:一项全人群数字健康方法的横断面分析。
Lancet Reg Health Am. 2023 Jun 22;23:100534. doi: 10.1016/j.lana.2023.100534. eCollection 2023 Jul.
3
Friedewald, Martin/Hopkins, or Sampson/NIH: Which is the Best Method to Estimate LDL-Cholesterol?

本文引用的文献

1
Cardiovascular Statistics - Brazil 2020.心血管统计数据 - 巴西2020年
Arq Bras Cardiol. 2020 Sep;115(3):308-439. doi: 10.36660/abc.20200812.
2
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.2019年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南:通过血脂修饰降低心血管风险
Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.
3
Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry.
弗里德瓦尔德法、马丁/霍普金斯法,还是桑普森/美国国立卫生研究院法:哪种是估算低密度脂蛋白胆固醇的最佳方法?
Arq Bras Cardiol. 2022 Aug;119(2):234-235. doi: 10.36660/abc.20220455.
4
Achievement of LDL-cholesterol Targets: Why do We Fail, and How Can We Improve?低密度脂蛋白胆固醇目标的达成:我们为何失败,又如何改进?
Arq Bras Cardiol. 2022 Jun 10;118(6):1026-1027. doi: 10.36660/abc.20220288.
5
Challenges faced by patients with dyslipidemia and systemic arterial hypertension in Brazil: a design of the patient journey.巴西血脂异常和全身性动脉高血压患者面临的挑战:患者旅程的设计。
BMC Cardiovasc Disord. 2022 May 21;22(1):237. doi: 10.1186/s12872-022-02669-8.
27 个国家的冠心病患者生活方式及对心血管危险因素控制的影响:欧洲心脏病学会 ESC-EORP EUROASPIRE V 注册研究结果。
Eur J Prev Cardiol. 2019 May;26(8):824-835. doi: 10.1177/2047487318825350. Epub 2019 Feb 10.
4
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2018 年美国心脏病学会/美国心脏协会/美国心血管血管造影和介入学会/美国预防、物理治疗和康复医师学会/美国糖尿病协会/美国老年学会/美国药学会/美国医师协会/美国生理学会/北美介入放射学会/美国国家脂质协会/美国临床内分泌医师协会胆固醇管理指南:美国心脏病学会/美国心脏协会临床实践指南工作组的报告。
Circulation. 2019 Jun 18;139(25):e1082-e1143. doi: 10.1161/CIR.0000000000000625. Epub 2018 Nov 10.
5
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017.全球、区域和国家按年龄、性别和死因分类的死亡率,195 个国家和地区,1980-2017 年:2017 年全球疾病负担研究的系统分析。
Lancet. 2018 Nov 10;392(10159):1736-1788. doi: 10.1016/S0140-6736(18)32203-7. Epub 2018 Nov 8.
6
American Association of Clinical Endocrinologists/American College of Endocrinology Management of Dyslipidemia and Prevention of Cardiovascular Disease Clinical Practice Guidelines.美国临床内分泌医师协会/美国内分泌学会血脂异常管理与心血管疾病预防临床实践指南
Diabetes Spectr. 2018 Aug;31(3):234-245. doi: 10.2337/ds18-0009.
7
The Brazilian health system at crossroads: progress, crisis and resilience.处于十字路口的巴西卫生系统:进步、危机与韧性。
BMJ Glob Health. 2018 Jul 3;3(4):e000829. doi: 10.1136/bmjgh-2018-000829. eCollection 2018.
8
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.依冠状动脉疾病严重程度和范围评估依洛尤单抗的临床获益:FOURIER 分析。
Circulation. 2018 Aug 21;138(8):756-766. doi: 10.1161/CIRCULATIONAHA.118.034309.
9
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.2017 年对 2016 年美国心脏病学会专家共识决策途径的重点更新:非他汀类药物在降低动脉粥样硬化性心血管疾病风险管理中的作用:美国心脏病学会专家组的专家共识决策途径报告。
J Am Coll Cardiol. 2017 Oct 3;70(14):1785-1822. doi: 10.1016/j.jacc.2017.07.745. Epub 2017 Sep 5.
10
[Not Available].[无可用内容]。
Arq Bras Cardiol. 2017 Jul;109(2 Supl 1):1-76. doi: 10.5935/abc.20170121.